Key Points Pharmaceutical giant Novo Nordisk just earned approval for an oral version of Wegovy. This could help improve its position in the increasingly competitive weight loss market. Despite some headwinds, there are several reasons to consider Novo Nordisk's stock. 10 stocks we like better than Novo Nordisk › The past 18 months have been challenging for Novo Nordisk (NYSE: NVO). Clinical setbacks, worse-than-expected financial results, and a loss of market share in its most important therape ...